WallStreetZenWallStreetZen

NASDAQ: NEUP
Neuphoria Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NEUP

Based on 1 analyst offering 12 month price targets for Neuphoria Therapeutics Inc

Min Forecast
$21.00+325.1%
Avg Forecast
$21.00+325.1%
Max Forecast
$21.00+325.1%

Should I buy or sell NEUP stock?

Based on 1 analyst offering ratings for Neuphoria Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NEUP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NEUP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NEUP stock forecasts and price targets.

NEUP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-04

1 of 1

Forecast return on equity

Is NEUP forecast to generate an efficient return?

Company
-27.64%
Industry
118.54%
Market
79.49%
NEUP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NEUP forecast to generate an efficient return on assets?

Company
-20.91%
Industry
38.01%
NEUP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NEUP earnings per share forecast

What is NEUP's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.56
Avg 2 year Forecast
-$1.85
Avg 3 year Forecast
-$1.21

NEUP revenue growth forecast

How is NEUP forecast to perform vs Biotechnology companies and vs the US market?

Company
127.33%
Industry
59.73%
Market
9.66%
NEUP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NEUP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NEUP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NEUP$4.94$21.00+325.10%Buy
BTAI$1.58$49.25+3,017.09%Buy
DWTX$4.56$10.00+119.30%Buy
INTS$0.57$6.75+1,088.38%Strong Buy
PHIO$1.80$4.00+122.22%Buy
View Top Biotech Stocks

Neuphoria Therapeutics Stock Forecast FAQ

Is Neuphoria Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NEUP) stock is to Buy NEUP stock.

Out of 1 analyst, 0 (0%) are recommending NEUP as a Strong Buy, 1 (100%) are recommending NEUP as a Buy, 0 (0%) are recommending NEUP as a Hold, 0 (0%) are recommending NEUP as a Sell, and 0 (0%) are recommending NEUP as a Strong Sell.

If you're new to stock investing, here's how to buy Neuphoria Therapeutics stock.

What is NEUP's earnings growth forecast for 2025-2027?

(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Neuphoria Therapeutics's earnings in 2025 is -$1,806,190.On average, 1 Wall Street analyst forecast NEUP's earnings for 2025 to be -$2,740,962, with the lowest NEUP earnings forecast at -$2,740,962, and the highest NEUP earnings forecast at -$2,740,962. On average, 1 Wall Street analyst forecast NEUP's earnings for 2026 to be -$3,250,500, with the lowest NEUP earnings forecast at -$3,250,500, and the highest NEUP earnings forecast at -$3,250,500.

In 2027, NEUP is forecast to generate -$2,126,003 in earnings, with the lowest earnings forecast at -$2,126,003 and the highest earnings forecast at -$2,126,003.

What is NEUP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NEUP) forecast ROE is -27.64%, which is considered weak.

What is NEUP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NEUP price target, the average NEUP price target is $21.00, with the highest NEUP stock price forecast at $21.00 and the lowest NEUP stock price forecast at $21.00.

The Wall Street analyst predicted that Neuphoria Therapeutics's share price could reach $21.00 by Feb 4, 2026. The average Neuphoria Therapeutics stock price prediction forecasts a potential upside of 325.1% from the current NEUP share price of $4.94.

What is NEUP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NEUP) Neuphoria Therapeutics's current Earnings Per Share (EPS) is -$2.56. On average, analysts forecast that NEUP's EPS will be -$1.56 for 2025, with the lowest EPS forecast at -$1.56, and the highest EPS forecast at -$1.56. On average, analysts forecast that NEUP's EPS will be -$1.85 for 2026, with the lowest EPS forecast at -$1.85, and the highest EPS forecast at -$1.85. In 2027, NEUP's EPS is forecast to hit -$1.21 (min: -$1.21, max: -$1.21).

What is NEUP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NEUP) forecast ROA is -20.91%, which is lower than the forecast US Biotechnology industry average of 38.01%.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.